Home > Oncology > ASCO 2020 > Genitourinary Cancer > Urothelial cancer: avelumab works as maintenance therapy

Urothelial cancer: avelumab works as maintenance therapy

Prof. Thomas Powles (Barts Cancer Institute, UK) presented the results of the phase 3, multicentre, multinational, randomised, open-label, parallel-arm JAVELIN Bladder 100 study in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line, platinum-containing chemotherapy. The study met its primary endpoint by showing significantly longer overall survival with avelumab first-line maintenance versus control, both in the overall population and the PD-L1+ population [1].

First-line, platinum-based chemotherapy for advance bladder cancer is characterised by frequent resistance, and PD-L1/PD-1 inhibitors, such as avelumab, are standard second-line treatment for patients with disease progression; however, only a minority of patients obtain a durable clinical benefit [2]. The JAVELIN Bladder 100 trial investigated avelumab as first-line...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on